Document is current
Any future updates will be listed below
-
Authors
Strassheimer, F.
Elleringmann, P.
Ludmirski, G.
Roller, B.
Macas, J.
Alekseeva, T.
Cakmak, P.
Aliraj, B.
Krenzlin, H.
Demes, M. C.
Mildenberger, I. C.
Tonn, T. https://orcid.org/0000-0001-9580-2193
Weber, K. J.
Reiss, Y.
Plate, K. H.
Weigert, A. https://orcid.org/0000-0002-7529-1952
Wels, W. S. https://orcid.org/0000-0001-9858-3643
Steinbach, J. P.
Burger, M. C. https://orcid.org/0000-0002-6927-0987
-
Funding
Funding for this research was provided by:
- LOEWE program, State of Hesse - Frankfurt Research Funding (FFF) - German Cancer Consortium (DKTK) - University Cancer Center Frankfurt
- License Information
-
More Information
Article History
Received: 5 June 2024
Revised: 2 February 2025
Accepted: 4 March 2025
First Online: 18 March 2025
Competing interests
: JPS has a consulting or advisory board membership with or has received honoraria or travel or accommodation expenses from AbbVie, Medac, Novocure, Roche, and UCB. TT and WSW are named as inventors on patents relating to NK-92/5.28.z cells jointly owned by their respective institutions. All other authors report no conflict of interest.
: All animal experiments were conducted in accordance with the guidelines and regulations of the German animal protection law and the European directive 2010/63/EU upon approval by the responsible government committee (Regierungspräsidium Darmstadt, Darmstadt, Germany, approval number FK-1088). The ARRIVE2.0 guideline criteria were met and are attached as supplementary information.
